Plasma markers of endothelial dysfunction in pulmonary hypertension

Chest

Volumn 120, Issue 4, 2001, Pages 1226-1230

  Cella, Giuseppe ^a   Bellotto, Fabio ^a   Tona, Francesco ^a   Sbarai, Alessandra ^a   Mazzaro, Gabriella ^a   Motta, Giovanna ^a   Fareed, Jawed ^b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Nitric oxide; Pulmonary hypertension; Selectins; Thrombomodulin; Tissue factor pathway inhibitor

Indexed keywords

NITRIC OXIDE; SELECTIN; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD LEVEL; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENDOTHELIUM CELL; FEMALE; HUMAN; LEUKOCYTE; LUNG ARTERY PRESSURE; MALE; PLASMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL; THROMBOCYTE;

EID: 0034799502     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.120.4.1226     Document Type: Article

References (36)

1. Endothelial dysfunction in pulmonary hypertension
2. Pathophysiology of pulmonary hypertension: A role of endothelial dysfunction
3. Pulmonary hypertension
4. Altered hemostasis in pulmonary hypertension
5. Prothrombotic mechanism in primary pulmonary hypertension
6. Endothelial modulation of pulmonary vascular tone
7. Anticoagulant property of the vascular endothelium
8. Assessment and treatment of endothelial dysfunction in humans
9. Evidence for local platelet activation in pulmonary vessels in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease
10. Platelet activation and fibrinopeptide formation in pulmonary hypertension
11. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension
12. Plasma levels of thrombomodulin in pulmonary hypertension
13. Colorimetric assays for nitric oxide and nitric oxide species formed from nitric oxide stock solutions and donor compounds
14. Endothelial cells-associated tissue factor pathway inhibitor (TFPI) antigen in severe non-diabetic obese patients: Effect of hyperinsulinemia
15. Soluble plasma thrombomodulin levels in patients with myeloproliferative disorder
16. Soluble P-Selectin in human plasma: Effect of anticoagulant matrix and its levels in patients with cardiovascular disorders
17. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension
18. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension
19. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension
20. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension
21. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: A case-cohort study
22. Soluble thrombomodulin as predictor of incident coronary heart disease
23. The selectins: Vascular adhesion molecules
24. Selectins and their ligands: Current concepts and controversies
25. Plasma P-selectin is increased in thrombotic consumptive platelet disorders
26. Increased soluble P-selectin following myocardial infarction: A new marker for the progression of atherosclerosis
27. Selectins in the HIT syndrome: Pathophysiologic role and therapeutic modulation
28. Increased soluble P-selectin levels following deep venous thrombosis: Cause or effect?
29. The pathogenesis of atherosclerosis: A perspective for the 1990s
30. Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions
31. The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transmural angioplasty
32. Nitric oxide physiology, pathophysiology and pharmacology
33. Tissue factor pathway inhibitor (TFPI): An update
34. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues
35. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions
36. Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration